Drugs / CE-326,597
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00576589 | Jan → Sep 2008 | obesity disorder | Pfizer | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00542009 | Dec 2007 → Nov 2008 | — | Pfizer | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CE-326,597 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00576589 ↗ |
| Action | Activate | “Cholecystokinin A receptor agonist” CHEMBL1269258 ↗ |
| Modality | Small molecule | — CHEMBL1269258 ↗ |
| Route | Oral | “Administered orally, once daily with morning meal for duration of trial (84 days).” NCT00542009 ↗ |
| Target | CCKAR | “Cholecystokinin A receptor agonist” CHEMBL1269258 ↗ |